Regeneron’s shares are down around 40% year to date. Was there something in the latest quarterly results that might ignite a rebound? Here are three things you need to know from Regeneron’s third-quarter update. Image source: Getty Images. 1. Eylea sales growth slowing More From Fool.com He Made 21,078% Buying Amazon. Heres His New Pick Regeneron reported revenue in the third quarter of $1.22 billion, up 7% year over year. Sales for Eylea made up 70% of total revenue. The good news is that the eye-disease drug saw sales climb 16% compared to the prior-year period, to $854 million. The bad news is that sales growth appears to be slowing.
For the original version including any supplementary images or video, visit http://www.foxbusiness.com/markets/2016/11/04/3-things-really-need-to-know-about-regeneron-pharmaceuticals-q3-results.html
Retinopathy.s a high risk for diabetics It is important to understand your risk of diabetic retinopathy. The spreading of a syphilis infection to the retinal blood vessels causes syphilitic retinopathy, and diabetes damages the retinal vessels resulting in a condition called diabetic retinopathy . http://www.oklahomasentinal.com/experteyedoctor/2016/11/01/basic-questions-on-painless-systems-of-glaucoma/Surgery often slows or stops the progression of diabetic retinopathy, but it’s not a cure. What if treatment doesn’t improve vision? About half of all people with diabetic retinopathy will develop DBE. Ongoing inflammation and vascular remodelling may occur over periods of time where the patient is not fully aware of the extent of the disease. Doppler optical coherence tomography. http://dclakers.com/aidengarciaville/2016/11/04/the-facts-for-2015-on-indispensable-elements-of-vitrectomy/After light passes through the cornea, it travels through a space called the anterior chamber which is filled with a protective fluid called the aqueous humour, through the pupil which is a hole in the iris, the coloured part of the eye, and then through a lens that performs more focusing.